BioCina and NovaCina Merger Strengthens Global CDMO Industry

Asian Aussie Business | Adelaide and Perth — The strategic combination between BioCina and NovaCina, two global contract development and manufacturing organizations (CDMOs), will create a formidable brand in the field of biopharmaceutical and small molecule contract manufacturing. Full integration will allow the merged company—which will keep the BioCina name—to provide the market a streamlined, end-to-end solution, covering everything from process and cell line discovery to clinical and commercial drug substance production as well as sterile fill-finish of pharmaceutical goods. Customers in the United States, Europe, Asia, and Australia, among others, are increasingly demanding integrated manufacturing solutions, and BioCina is well-positioned to provide them with this expanded package of services.

The merger brings together BioCina’s renowned knowledge of microbial, plasmid DNA, and mRNA modalities as well as NovaCina’s cutting-edge sterile fill-finish plant in Perth, Western Australia, which has manufactured over 600 biologic and small molecule products. The synergistic union offers a simplified, client-centric experience, controlled by a single company, and clients are serviced by expert technical SMEs with an average tenure of over 10 years. Today, BioCina stands on three pillars: its agile, phase-appropriate solutions, its high quality, and its industry-leading on-time and in-full (OTIF) delivery reliability. FDA, EMA, TGA, and Health Canada approvals are only a few of BioCina’s impressive regulatory accomplishments. Drug developers will also be able to take advantage of Australia’s leading tax incentive, which offers a rebate of up to 48.5% for CDMO projects in the country.

Mark W. Womack will remain CEO of BioCina. He has presided over the company’s meteoric rise and expansion in the past two years. Throughout his career, Womack has been widely acknowledged for his forward-thinking leadership, which has resulted in a client-centric culture and consistently high operational performance for a number of thriving businesses. Womack was key in the expansion of AGC Biologics during his time as chief business officer and his previous positions as chief executive officer of KBI Biopharma, Stelis Biopharma, and AGC Biologics.

We are quite optimistic about the future of these two businesses as a combined entity, particularly with Mark leading the charge, because of how well they mesh with one another. There has been a dramatic uptick in the complexity and rate of change within the industry. In order to expedite the regulatory approval process and bring their medicines to market, both new drug developers and established biopharma businesses are seeking a reliable contract development and manufacturing organization (CDMO) partner. You can’t go wrong with any of these companies. According to Masood Tayebi, Co-Founder and CEO of the Bridgewest Group—the parent business of both firms—working together, they will enhance the industry’s skills and standards while providing an unmatched service.

I am pleased to be the leader of this innovative new company. “This merger further strengthens our position as the most dependable and client-centric end-to-end CDMO for the global biopharmaceutical and small molecule industry,” stated Mark W. Womack, CEO of BioCina.

Regarding the Latest BioCina

BioCina is a world-renowned CDMO that provides clients with unmatched quality, strict compliance with regulations, and the best on-time and complete delivery rates in the business. They are known for being dependable and setting new benchmarks for the industry. Among BioCina’s extensive list of services is the development of cell lines, processes, analytical tools, formulations, and cGMP clinical and commercial production. The company’s experts in small compounds, microbes, pDNA, and mRNA modalities are invaluable.

Adelaide and Perth are home to two of Australia’s most cutting-edge facilities, which are run by BioCina. With a staff of Subject Matter Experts (SMEs) that have been there, on average, for over ten years, the facilities have a long history of creating and producing pharmaceutical substances and products for both clinical and commercial use.

BioCina consistently meets or exceeds all international quality standards. The Australian TGA has granted licenses for the cGMP production of bulk drug substances and sterile drug products, and the facilities have been inspected and found to be in compliance with regulations by the US FDA, EMA, and Health Canada. With a history of success, BioCina has supplied 98 nations throughout the Americas, Europe, Asia, and Africa with its high-quality pharmaceutical products.

BioCina takes great pride in servicing clients from all major global markets. Since BioCina is not involved in drug development, it is able to dedicate its entire attention to assisting its clients’ goods.

Australia is a great place for pharmaceutical companies to invest in production and scaling up because it has one of the best tax incentives in the world (up to 48.5% cash rebate).

In 2024, BioCina was honored with the “Emerging Business of the Year” award in South Australia for its rapid growth in the biopharmaceutical business.

Visit https://biocina.com to find out more.

Email: media@biocina.com

Source: BioCina